{"pmid":32473600,"title":"Mechanism of baricitinib supports artificial intelligence-predicted testing in COVID-19 patients.","text":["Mechanism of baricitinib supports artificial intelligence-predicted testing in COVID-19 patients.","Baricitinib, is an oral Janus kinase (JAK)1/JAK2 inhibitor approved for the treatment of rheumatoid arthritis (RA) that was independently predicted, using artificial intelligence (AI)-algorithms, to be useful for COVID-19 infection via a proposed anti-cytokine effects and as an inhibitor of host cell viral propagation. We evaluated the in vitro pharmacology of baricitinib across relevant leukocyte subpopulations coupled to its in vivo pharmacokinetics and showed it inhibited signaling of cytokines implicated in COVID-19 infection. We validated the AI-predicted biochemical inhibitory effects of baricitinib on human numb-associated kinase (hNAK) members measuring nanomolar affinities for AAK1, BIKE, and GAK. Inhibition of NAKs led to reduced viral infectivity with baricitinib using human primary liver spheroids. These effects occurred at exposure levels seen clinically. In a case series of patients with bilateral COVID-19 pneumonia, baricitinib treatment was associated with clinical and radiologic recovery, a rapid decline in SARS-CoV-2 viral load, inflammatory markers, and IL-6 levels. Collectively, these data support further evaluation of the anti-cytokine and anti-viral activity of baricitinib and supports its assessment in randomized trials in hospitalized COVID-19 patients.","EMBO Mol Med","Stebbing, Justin","Krishnan, Venkatesh","de Bono, Stephanie","Ottaviani, Silvia","Casalini, Giacomo","Richardson, Peter J","Monteil, Vanessa","Lauschke, Volker M","Mirazimi, Ali","Youhanna, Sonia","Tan, Yee-Joo","Baldanti, Fausto","Sarasini, Antonella","Terres, Jorge A Ross","Nickoloff, Brian J","Higgs, Richard E","Rocha, Guilherme","Byers, Nicole L","Schlichting, Douglas E","Nirula, Ajay","Cardoso, Anabela","Corbellino, Mario","32473600"],"abstract":["Baricitinib, is an oral Janus kinase (JAK)1/JAK2 inhibitor approved for the treatment of rheumatoid arthritis (RA) that was independently predicted, using artificial intelligence (AI)-algorithms, to be useful for COVID-19 infection via a proposed anti-cytokine effects and as an inhibitor of host cell viral propagation. We evaluated the in vitro pharmacology of baricitinib across relevant leukocyte subpopulations coupled to its in vivo pharmacokinetics and showed it inhibited signaling of cytokines implicated in COVID-19 infection. We validated the AI-predicted biochemical inhibitory effects of baricitinib on human numb-associated kinase (hNAK) members measuring nanomolar affinities for AAK1, BIKE, and GAK. Inhibition of NAKs led to reduced viral infectivity with baricitinib using human primary liver spheroids. These effects occurred at exposure levels seen clinically. In a case series of patients with bilateral COVID-19 pneumonia, baricitinib treatment was associated with clinical and radiologic recovery, a rapid decline in SARS-CoV-2 viral load, inflammatory markers, and IL-6 levels. Collectively, these data support further evaluation of the anti-cytokine and anti-viral activity of baricitinib and supports its assessment in randomized trials in hospitalized COVID-19 patients."],"journal":"EMBO Mol Med","authors":["Stebbing, Justin","Krishnan, Venkatesh","de Bono, Stephanie","Ottaviani, Silvia","Casalini, Giacomo","Richardson, Peter J","Monteil, Vanessa","Lauschke, Volker M","Mirazimi, Ali","Youhanna, Sonia","Tan, Yee-Joo","Baldanti, Fausto","Sarasini, Antonella","Terres, Jorge A Ross","Nickoloff, Brian J","Higgs, Richard E","Rocha, Guilherme","Byers, Nicole L","Schlichting, Douglas E","Nirula, Ajay","Cardoso, Anabela","Corbellino, Mario"],"date":"2020-05-31T11:00:00Z","year":2020,"_id":"32473600","source":"PubMed","week":"202022|May 25 - May 31","doi":"10.15252/emmm.202012697","keywords":["baricitinib","covid-19","anti-cytokine","anti-viral","case series"],"locations":["Janus"],"topics":["Treatment","Mechanism"],"weight":1,"_version_":1668255193347653632,"score":9.490897,"similar":[{"pmid":32392562,"title":"JAK Inhibition as a New Treatment Strategy for Patients with COVID-19.","text":["JAK Inhibition as a New Treatment Strategy for Patients with COVID-19.","After the advent of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), the outbreak of coronavirus disease 2019 (COVID-19) commenced across the world. Understanding the Immunopathogenesis of COVID-19 is essential for interrupting viral infectivity and preventing aberrant immune responses before a vaccine can be developed. In this review, we provide the latest insights into the roles of angiotensin-converting enzyme II (ACE2) and Ang II receptor-1 (AT1-R) in this disease. Novel therapeutic strategies, including recombinant ACE2, ACE inhibitors, AT1-R blockers, and Ang 1-7 peptides, may prevent or reduce viruses-induced pulmonary, cardiac, and renal injuries. However, more studies are needed to clarify the efficacy of these therapeutics. Furthermore, considering the common role of the Janus kinase-signal transducer and activator of transcription (JAK-STAT) pathway in AT1-R expressed on peripheral tissues and cytokine receptors on the surface of immune cells, potential targeting of this pathway using JAK inhibitors (JAKinibs) is suggested as a promising approach in patients with COVID-19 who are admitted to hospitals. In addition to antiviral therapy, potential ACE2- and AT1-R-inhibiting strategies, and other supportive care, we suggest other potential JAKinibs and novel anti-inflammatory combination therapies that affect the JAK-STAT pathway in patients with COVID-19. Since the combination of MTX and baricitinib leads to outstanding clinical outcomes, the addition of baricitinib to MTX might be a potential strategy.","Int Arch Allergy Immunol","Seif, Farhad","Aazami, Hossein","Khoshmirsafa, Majid","Kamali, Monireh","Mohsenzadegan, Monireh","Pornour, Majid","Mansouri, Davood","32392562"],"abstract":["After the advent of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), the outbreak of coronavirus disease 2019 (COVID-19) commenced across the world. Understanding the Immunopathogenesis of COVID-19 is essential for interrupting viral infectivity and preventing aberrant immune responses before a vaccine can be developed. In this review, we provide the latest insights into the roles of angiotensin-converting enzyme II (ACE2) and Ang II receptor-1 (AT1-R) in this disease. Novel therapeutic strategies, including recombinant ACE2, ACE inhibitors, AT1-R blockers, and Ang 1-7 peptides, may prevent or reduce viruses-induced pulmonary, cardiac, and renal injuries. However, more studies are needed to clarify the efficacy of these therapeutics. Furthermore, considering the common role of the Janus kinase-signal transducer and activator of transcription (JAK-STAT) pathway in AT1-R expressed on peripheral tissues and cytokine receptors on the surface of immune cells, potential targeting of this pathway using JAK inhibitors (JAKinibs) is suggested as a promising approach in patients with COVID-19 who are admitted to hospitals. In addition to antiviral therapy, potential ACE2- and AT1-R-inhibiting strategies, and other supportive care, we suggest other potential JAKinibs and novel anti-inflammatory combination therapies that affect the JAK-STAT pathway in patients with COVID-19. Since the combination of MTX and baricitinib leads to outstanding clinical outcomes, the addition of baricitinib to MTX might be a potential strategy."],"journal":"Int Arch Allergy Immunol","authors":["Seif, Farhad","Aazami, Hossein","Khoshmirsafa, Majid","Kamali, Monireh","Mohsenzadegan, Monireh","Pornour, Majid","Mansouri, Davood"],"date":"2020-05-12T11:00:00Z","year":2020,"_id":"32392562","source":"PubMed","week":"202020|May 11 - May 17","doi":"10.1159/000508247","keywords":["angiotensin receptor blocker","angiotensin-converting enzyme inhibitor","bricitinib","cytokine","jak inhibitors","jak-stat pathway","methotrexate"],"topics":["Treatment","Mechanism"],"weight":1,"_version_":1666528579989536769,"score":402.76404},{"pmid":32259575,"pmcid":"PMC7128600","title":"Janus kinase inhibitor baricitinib is not an ideal option for management of COVID-19.","text":["Janus kinase inhibitor baricitinib is not an ideal option for management of COVID-19.","The Wuhan outbreak of novel Corona virus infection has been the global focus since December 2019. This infection has become a global pandemic. It is highly important to understand the virology of the pathogen and to explore the therapeutic options for management of this pandemic. Drug repurposing strategies are being considered for management of COVID 19. Among the identified drugs, Baricitinib has become a keen interest for researchers because of its ability to inhibit the viral assembly by the prevention of Clarithrin associated endocytosis. We tried to explore the reasons on why Baricitinib is not an ideal option for COVID 19.","Int J Antimicrob Agents","Praveen, D","Puvvada, Ranadheer Chowdary","M, Vijey Aanandhi","32259575"],"abstract":["The Wuhan outbreak of novel Corona virus infection has been the global focus since December 2019. This infection has become a global pandemic. It is highly important to understand the virology of the pathogen and to explore the therapeutic options for management of this pandemic. Drug repurposing strategies are being considered for management of COVID 19. Among the identified drugs, Baricitinib has become a keen interest for researchers because of its ability to inhibit the viral assembly by the prevention of Clarithrin associated endocytosis. We tried to explore the reasons on why Baricitinib is not an ideal option for COVID 19."],"journal":"Int J Antimicrob Agents","authors":["Praveen, D","Puvvada, Ranadheer Chowdary","M, Vijey Aanandhi"],"date":"2020-04-08T11:00:00Z","year":2020,"_id":"32259575","source":"PubMed","week":"202015|Apr 06 - Apr 12","doi":"10.1016/j.ijantimicag.2020.105967","keywords":["baricitinib","covid 19","novel corona virus","sars-cov-2"],"locations":["Wuhan","Clarithrin","Janus"],"countries":["China"],"countries_codes":["CHN|China"],"e_drugs":["baricitinib"],"topics":["Mechanism","Treatment"],"weight":1,"_version_":1666138493153181697,"score":379.2866},{"pmid":32253068,"pmcid":"PMC7127009","title":"Recommendations for coronavirus infection in rheumatic diseases treated with biologic therapy.","text":["Recommendations for coronavirus infection in rheumatic diseases treated with biologic therapy.","The Coronavirus-associated disease, that was first identified in 2019 in China (CoViD-19), is a pandemic caused by a bat-derived beta-coronavirus, named SARS-CoV2. It shares homology with SARS and MERS-CoV, responsible for past outbreaks in China and in Middle East. SARS-CoV2 spread from China where the first infections were described in December 2019 and is responsible for the respiratory symptoms that can lead to acute respiratory distress syndrome. A cytokine storm has been shown in patients who develop fatal complications, as observed in past coronavirus infections. The management includes ventilatory support and broad-spectrum antiviral drugs, empirically utilized, as a targeted therapy and vaccines have not been developed. Based upon our limited knowledge on the pathogenesis of CoViD-19, a potential role of some anti-rheumatic drugs may be hypothesized, acting as direct antivirals or targeting host immune response. Antimalarial drugs, commonly used in rheumatology, may alter the lysosomal proteases that mediates the viral entry into the cell and have demonstrated efficacy in improving the infection. Anti-IL-1 and anti-IL-6 may interfere with the cytokine storm in severe cases and use of tocilizumab has shown good outcomes in a small cohort. Baricitinib has both antiviral and anti-inflammatory properties. Checkpoints inhibitors such as anti-CD200 and anti-PD1 could have a role in the treatment of CoViD-19. Rheumatic disease patients taking immunosuppressive drugs should be recommended to maintain the chronic therapy, prevent infection by avoiding social contacts and pausing immunosuppressants in case of infection. National and international registries are being created to collect data on rheumatic patients with CoViD-19.","J Autoimmun","Ceribelli, Angela","Motta, Francesca","De Santis, Maria","Ansari, Aftab A","Ridgway, William M","Gershwin, M Eric","Selmi, Carlo","32253068"],"abstract":["The Coronavirus-associated disease, that was first identified in 2019 in China (CoViD-19), is a pandemic caused by a bat-derived beta-coronavirus, named SARS-CoV2. It shares homology with SARS and MERS-CoV, responsible for past outbreaks in China and in Middle East. SARS-CoV2 spread from China where the first infections were described in December 2019 and is responsible for the respiratory symptoms that can lead to acute respiratory distress syndrome. A cytokine storm has been shown in patients who develop fatal complications, as observed in past coronavirus infections. The management includes ventilatory support and broad-spectrum antiviral drugs, empirically utilized, as a targeted therapy and vaccines have not been developed. Based upon our limited knowledge on the pathogenesis of CoViD-19, a potential role of some anti-rheumatic drugs may be hypothesized, acting as direct antivirals or targeting host immune response. Antimalarial drugs, commonly used in rheumatology, may alter the lysosomal proteases that mediates the viral entry into the cell and have demonstrated efficacy in improving the infection. Anti-IL-1 and anti-IL-6 may interfere with the cytokine storm in severe cases and use of tocilizumab has shown good outcomes in a small cohort. Baricitinib has both antiviral and anti-inflammatory properties. Checkpoints inhibitors such as anti-CD200 and anti-PD1 could have a role in the treatment of CoViD-19. Rheumatic disease patients taking immunosuppressive drugs should be recommended to maintain the chronic therapy, prevent infection by avoiding social contacts and pausing immunosuppressants in case of infection. National and international registries are being created to collect data on rheumatic patients with CoViD-19."],"journal":"J Autoimmun","authors":["Ceribelli, Angela","Motta, Francesca","De Santis, Maria","Ansari, Aftab A","Ridgway, William M","Gershwin, M Eric","Selmi, Carlo"],"date":"2020-04-08T11:00:00Z","year":2020,"_id":"32253068","source":"PubMed","week":"202015|Apr 06 - Apr 12","doi":"10.1016/j.jaut.2020.102442","keywords":["antimalarials","baricitinib","covid-19","rheumatic diseases","sars-cov2","tocilizumab"],"locations":["China","China","China"],"countries":["China"],"countries_codes":["CHN|China"],"e_drugs":["tocilizumab","baricitinib"],"topics":["Mechanism","Treatment"],"weight":1,"_version_":1666138493115432961,"score":269.5716},{"pmid":32341791,"pmcid":"PMC7174058","title":"Thoughts on COVID-19 and autoimmune diseases.","text":["Thoughts on COVID-19 and autoimmune diseases.","Over the 2 months since coronavirus first appeared in China, cases have emerged on every continent, and it is clear that patients with autoimmune diseases might also be affected. Coronavirus disease 2019 (COVID-19) is a highly contagious viral illness with a mortality rate approaching 2%. Here we discuss the challenges that patients with autoimmune diseases might face and the information on using immunomodulatory therapies like chloroquine, tocilizumab and baricitinib to quench the cytokine storm in patients with very severe COVID-19 pneumonia.","Lupus Sci Med","Askanase, Anca D","Khalili, Leila","Buyon, Jill P","32341791"],"abstract":["Over the 2 months since coronavirus first appeared in China, cases have emerged on every continent, and it is clear that patients with autoimmune diseases might also be affected. Coronavirus disease 2019 (COVID-19) is a highly contagious viral illness with a mortality rate approaching 2%. Here we discuss the challenges that patients with autoimmune diseases might face and the information on using immunomodulatory therapies like chloroquine, tocilizumab and baricitinib to quench the cytokine storm in patients with very severe COVID-19 pneumonia."],"journal":"Lupus Sci Med","authors":["Askanase, Anca D","Khalili, Leila","Buyon, Jill P"],"date":"2020-04-29T11:00:00Z","year":2020,"_id":"32341791","source":"PubMed","week":"202018|Apr 27 - May 03","doi":"10.1136/lupus-2020-000396","keywords":["autoimmune diseases","cytokines","inflammation"],"locations":["China"],"countries":["China"],"countries_codes":["CHN|China"],"e_drugs":["Chloroquine","tocilizumab","baricitinib"],"topics":["Treatment"],"weight":1,"_version_":1666138495775670272,"score":248.85796},{"pmid":32426387,"pmcid":"PMC7227517","title":"Artificial intelligence approach fighting COVID-19 with repurposing drugs.","text":["Artificial intelligence approach fighting COVID-19 with repurposing drugs.","Background: The ongoing COVID-19 pandemic has caused more than 193,825 deaths during the past few months. A quick-to-be-identified cure for the disease will be a therapeutic medicine that has prior use experiences in patients in order to resolve the current pandemic situation before it could become worsening. Artificial intelligence (AI) technology is hereby applied to identify the marketed drugs with potential for treating COVID-19. Material and methods: An AI platform was established to identify potential old drugs with anti-coronavirus activities by using two different learning databases; one consisted of the compounds reported or proven active against SARS-CoV, SARS-CoV-2, human immunodeficiency virus, influenza virus, and the other one containing the known 3C-like protease inhibitors. All AI predicted drugs were then tested for activities against a feline coronavirus in in vitro cell-based assay. These assay results were feedbacks to the AI system for relearning and thus to generate a modified AI model to search for old drugs again. Results: After a few runs of AI learning and prediction processes, the AI system identified 80 marketed drugs with potential. Among them, 8 drugs (bedaquiline, brequinar, celecoxib, clofazimine, conivaptan, gemcitabine, tolcapone, and vismodegib) showed in vitro activities against the proliferation of a feline infectious peritonitis (FIP) virus in Fcwf-4 cells. In addition, 5 other drugs (boceprevir, chloroquine, homoharringtonine, tilorone, and salinomycin) were also found active during the exercises of AI approaches. Conclusion: Having taken advantages of AI, we identified old drugs with activities against FIP coronavirus. Further studies are underway to demonstrate their activities against SARS-CoV-2 in vitro and in vivo at clinically achievable concentrations and doses. With prior use experiences in patients, these old drugs if proven active against SARS-CoV-2 can readily be applied for fighting COVID-19 pandemic.","Biomed J","Ke, Yi-Yu","Peng, Tzu-Ting","Yeh, Teng-Kuang","Huang, Wen-Zheng","Chang, Shao-En","Wu, Szu-Huei","Hung, Hui-Chen","Hsu, Tsu-An","Lee, Shiow-Ju","Song, Jeng-Shin","Lin, Wen-Hsing","Chiang, Tung-Jung","Lin, Jiunn-Horng","Sytwu, Huey-Kang","Chen, Chiung-Tong","32426387"],"abstract":["Background: The ongoing COVID-19 pandemic has caused more than 193,825 deaths during the past few months. A quick-to-be-identified cure for the disease will be a therapeutic medicine that has prior use experiences in patients in order to resolve the current pandemic situation before it could become worsening. Artificial intelligence (AI) technology is hereby applied to identify the marketed drugs with potential for treating COVID-19. Material and methods: An AI platform was established to identify potential old drugs with anti-coronavirus activities by using two different learning databases; one consisted of the compounds reported or proven active against SARS-CoV, SARS-CoV-2, human immunodeficiency virus, influenza virus, and the other one containing the known 3C-like protease inhibitors. All AI predicted drugs were then tested for activities against a feline coronavirus in in vitro cell-based assay. These assay results were feedbacks to the AI system for relearning and thus to generate a modified AI model to search for old drugs again. Results: After a few runs of AI learning and prediction processes, the AI system identified 80 marketed drugs with potential. Among them, 8 drugs (bedaquiline, brequinar, celecoxib, clofazimine, conivaptan, gemcitabine, tolcapone, and vismodegib) showed in vitro activities against the proliferation of a feline infectious peritonitis (FIP) virus in Fcwf-4 cells. In addition, 5 other drugs (boceprevir, chloroquine, homoharringtonine, tilorone, and salinomycin) were also found active during the exercises of AI approaches. Conclusion: Having taken advantages of AI, we identified old drugs with activities against FIP coronavirus. Further studies are underway to demonstrate their activities against SARS-CoV-2 in vitro and in vivo at clinically achievable concentrations and doses. With prior use experiences in patients, these old drugs if proven active against SARS-CoV-2 can readily be applied for fighting COVID-19 pandemic."],"journal":"Biomed J","authors":["Ke, Yi-Yu","Peng, Tzu-Ting","Yeh, Teng-Kuang","Huang, Wen-Zheng","Chang, Shao-En","Wu, Szu-Huei","Hung, Hui-Chen","Hsu, Tsu-An","Lee, Shiow-Ju","Song, Jeng-Shin","Lin, Wen-Hsing","Chiang, Tung-Jung","Lin, Jiunn-Horng","Sytwu, Huey-Kang","Chen, Chiung-Tong"],"date":"2020-05-20T11:00:00Z","year":2020,"_id":"32426387","source":"PubMed","week":"202021|May 18 - May 24","doi":"10.1016/j.bj.2020.05.001","keywords":["ai","covid-19","dnn","drug repurposing","feline coronavirus","sars-cov-2"],"locations":["feline","vitro","vismodegib","vivo"],"e_drugs":["HhAntag691","Tolcapone","Homoharringtonine","salinomycin","gemcitabine","conivaptan","N-(3-amino-1-(cyclobutylmethyl)-2,3-dioxopropyl)-3-(2-((((1,1-dimethylethyl)amino)carbonyl)amino)-3,3-dimethyl-1-oxobutyl)-6,6-dimethyl-3-azabicyclo(3.1.0)hexan-2-carboxamide","Chloroquine","Tilorone","brequinar","Celecoxib","bedaquiline","Clofazimine"],"topics":["Treatment"],"weight":1,"_version_":1667352728728240130,"score":228.63416}]}